2024
326-OR: Activity Feature Attenuates Drop in Glucose for Individuals with Type 1 Diabetes Using Omnipod 5 Automated Insulin Delivery System
TURNER L, SHERR J, ZAHARIEVA D, BARAN J, BODE B, BROWN S, BZDICK S, MEI CHURCH M, HANSEN D, KINGMAN R, LAFFEL L, SHAH V, STONE S, VIENNEAU T, HUYETT L, DUMAIS B, LY T, RIDDELL M, 5 EXERCISE RESEARCH GROUP O. 326-OR: Activity Feature Attenuates Drop in Glucose for Individuals with Type 1 Diabetes Using Omnipod 5 Automated Insulin Delivery System. Diabetes 2024, 73 DOI: 10.2337/db24-326-or.Peer-Reviewed Original ResearchGeneralized estimating equationsInternational Society for Pediatric and Adolescent DiabetesActivity sessionsEstimating equationsType 1 diabetesExerciseAdolescent DiabetesAF-30Glucose declineDeliveryInsulin deliveryInsuletSessionsDelivery systemInsulin delivery systemsDiabetesAutomated deliveryOmnipodRiskGlucoseT1DPeople240-OR: Longitudinal Assessment of Glycemia and Severe Hypoglycemia among Adults with Type 1 Diabetes—An Online Survey
SHERR J, HAGAN K, BHAK R, PETER M, NGUYEN H, WANG C, PAKALAPATI T, SHERWOOD J, GUPTA T, GAGLIA J, CORNELIUS E, CHAPMAN K, WOLF W, PETTUS J. 240-OR: Longitudinal Assessment of Glycemia and Severe Hypoglycemia among Adults with Type 1 Diabetes—An Online Survey. Diabetes 2024, 73 DOI: 10.2337/db24-240-or.Peer-Reviewed Original ResearchFollow-up surveySevere hypoglycemic eventsImpaired awareness of hypoglycemiaOnline surveyT1D Exchange RegistryProportion of respondentsT1D careFollow-upEligible individualsHbA1c < 7%Diabetes technologyLongitudinal trendsCGM useHbA1c targetLongitudinal assessmentInsulin delivery methodsHbA1cAwareness of hypoglycemiaSurveyParticipantsImpaired awarenessAdultsT1DRespondentsHypoglycemic eventsDigital Gaming and Exercise Among Youth With Type 1 Diabetes: Cross-Sectional Analysis of Data From the Type 1 Diabetes Exercise Initiative Pediatric Study
Patton S, Gal R, Bergford S, Calhoun P, Clements M, Sherr J, Riddell M. Digital Gaming and Exercise Among Youth With Type 1 Diabetes: Cross-Sectional Analysis of Data From the Type 1 Diabetes Exercise Initiative Pediatric Study. JMIR Pediatrics And Parenting 2024, 7: e57198. PMID: 38889077, PMCID: PMC11186795, DOI: 10.2196/57198.Peer-Reviewed Original ResearchExercise sessionsPhysical activityMinutes of physical activityLevels of physical activityRegular physical activityType 1 diabetesCross-sectional analysisDigital gamesHealthy lifestyleActive wearablesGame sessionsExerciseInsulin useNondigital gamesDaily activitiesPediatric studiesSessionsContext of youthDisease statusYouthT1DCharacteristics of digital gamesInsulin pumpObservation periodContinuous glucose monitoringPredicting Hypoglycemia and Hyperglycemia Risk During and After Activity for Adolescents with Type 1 Diabetes
Bergford S, Riddell M, Gal R, Patton S, Clements M, Sherr J, Calhoun P. Predicting Hypoglycemia and Hyperglycemia Risk During and After Activity for Adolescents with Type 1 Diabetes. Diabetes Technology & Therapeutics 2024, 26: 728-738. PMID: 38669475, DOI: 10.1089/dia.2024.0061.Peer-Reviewed Original ResearchRepeated measures logistic regressionPhysically active adolescentsHyperglycemia riskType 1 diabetesMeasures logistic regressionComposite riskAcute glucose responseGlucose rateWearing continuous glucose monitoringContinuous glucose monitoringReceiver operating characteristic curveArea under the receiver operating characteristic curveRisk of hypoglycemiaLogistic regressionActive adolescentsHbA1c levelsActivity startExerciseAdolescentsRiskCharacteristic curveHypoglycemiaGlucose responseHyperglycemiaT1DReal-World Evidence of Omnipod® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes
Forlenza G, DeSalvo D, Aleppo G, Wilmot E, Berget C, Huyett L, Hadjiyianni I, Méndez J, Conroy L, Ly T, Sherr J. Real-World Evidence of Omnipod® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes. Diabetes Technology & Therapeutics 2024, 26: 514-525. PMID: 38375861, DOI: 10.1089/dia.2023.0578.Peer-Reviewed Original ResearchGlucose targetsType 1 diabetesSubgroup analysisGlycemic outcomesReal-world evidenceMultiple daily injectionsYounger age groupsBaseline characteristicsDaily injectionsRetrospective analysisClinical trialsMedian percentageAge groupsResults:</i></b>OmnipodDelivery systemOutcomesInsulin delivery systemsT1DSubgroupsDiverse samplePostprandial Glucose Variability Following Typical Meals in Youth Living with Type 1 Diabetes
Patton S, Bergford S, Sherr J, Gal R, Calhoun P, Clements M, Riddell M, Martin C. Postprandial Glucose Variability Following Typical Meals in Youth Living with Type 1 Diabetes. Nutrients 2024, 16: 162. PMID: 38201991, PMCID: PMC10781146, DOI: 10.3390/nu16010162.Peer-Reviewed Original ResearchConceptsGlycemic variabilityGlucose variabilityType 1Continuous glucose monitoringPediatric studiesCarbohydrate intakeDay observation periodMacronutrient intakeDietary guidelinesPhysical activityExercise intensityT1DGlucose monitoringObservation periodTypical mealMeal contentMealIntakeCoefficient of variationAssociationMacronutrient contentMore carbohydratesCliniciansLarge sample
2022
765-P: Glycemic Outcomes across Total Daily Insulin Doses with the Omnipod 5 Automated Insulin Delivery System (AID) among People with Type 1 Diabetes (T1D) Ages 2 to 70 Years
SCHOELWER M, BODE B, CARLSON A, CRIEGO A, FORLENZA G, WEINSTOCK R, HANSEN D, BUCKINGHAM B, MEHTA S, LAFFEL L, SHERR J, LEVY C, HIRSCH I, MACLEISH S, DESALVO D, SHAH V, BHARGAVA A, JONES T, ALEPPO G, GURLIN R, LY T. 765-P: Glycemic Outcomes across Total Daily Insulin Doses with the Omnipod 5 Automated Insulin Delivery System (AID) among People with Type 1 Diabetes (T1D) Ages 2 to 70 Years. Diabetes 2022, 71 DOI: 10.2337/db22-765-p.Peer-Reviewed Original ResearchDaily insulin doseMannKind CorporationInsulin doseGlycemic outcomesEvaluate glycemic outcomesHigher TIRNational Institute of DiabetesDigestive and Kidney DiseasesCenter for Health ResearchType 1 diabetesEli Lilly and CompanySpeakers bureauInsulin requirementsAid useKidney diseaseInsulin needsMannKindCohort of peopleMedtronicTherapy phaseAged 2Janssen PharmaceuticalsOlder ageDiabetesT1DPharmacodynamics, pharmacokinetics, safety, and tolerability of a ready‐to‐use, room temperature, liquid stable glucagon administered via an autoinjector pen to youth with type 1 diabetes
Buckingham B, Sherr J, Prestrelski S, Conoscenti V. Pharmacodynamics, pharmacokinetics, safety, and tolerability of a ready‐to‐use, room temperature, liquid stable glucagon administered via an autoinjector pen to youth with type 1 diabetes. Pediatric Diabetes 2022, 23: 754-762. PMID: 35562186, DOI: 10.1111/pedi.13360.Peer-Reviewed Original ResearchConceptsPlasma glucose concentrationType 1 diabetesAged 2 to <Common adverse eventsAge-appropriate dosesGlucose concentrationGlucagon formulationsManagement of hypoglycemiaPrimary endpointAdverse eventsMedical complicationsPK parametersPharmacodynamicsPharmacokineticsReady-to-useT1DGlucagonHypoglycemiaAge cohortsCohortAutoinjectorPlasmaBaselineAgeYears
2021
Adjunctive Therapies for Type 1 Diabetes
Nally L, Van Name M, Tamborlane W, Sherr J. Adjunctive Therapies for Type 1 Diabetes. Contemporary Endocrinology 2021, 143-150. DOI: 10.1007/978-3-030-64133-7_13.Chapters